MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma
Metrics: PDF 1443 views | HTML 2863 views | ?
Wende Li1,2,4, Weining Yang3, Yujiao Liu2, Siyu Chen4, Shanmin Chin2, Xiaolong Qi2, Yingchao Zhao5, Hao Liu2, Jiasheng Wang1, Xueting Mei1, Peigen Huang2 and Donghui Xu1
1Laboratory of Traditional Chinese Medicine and Marine Drugs, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510275, China
2Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
3Sunnybrook Health Sciences Centre and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
4Guangdong Laboratory Animals Monitoring Institute, Guangdong Key Laboratory of Laboratory Animals, Guangzhou 510663, China
5Cancer center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Donghui Xu, email: [email protected]
Keywords: miR-378, glioblastoma, U87, curcumin
Received: December 29, 2016 Accepted: March 30, 2017 Published: May 16, 2017
Glioblastoma multiforme is the most aggressive and common primary brain tumor, and is virtually incurable due to its therapeutic resistance to radiation and chemotherapy. Curcumin is a well-known phytochemical exhibiting antitumor activity on many human cancers including glioblastoma multiforme. Given the unique miRNA expression profiles in cancer cells compared to non-cancerous cells, we investigated whether these miRNA could be used to cancer therapy. In this report we show that miR-378, a glioblastoma multiforme down regulated miRNA, may enhance the inhibitory effect of curcumin on this cancer growth. Our results indicated that the inhibitory effect of curcumin was enhanced in miR-378-expressing stable U87 cells in vitro and in vivo, compared to control cells. MiR-378 was found to target p-p38 expression, underlying the observed phenotypic changes. Thus, we concluded that miR-378 enhances the response of glioblastoma multiforme to curcumin treatment, by targeting p38.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.